Imagine your baby has diabetes that shows up in the first months of life. Doctors often try a drug called glibenclamide instead of insulin shots. But for two infants with a rare condition called iDEND syndrome and a specific change in the KCNJ11 gene, that drug didn't work.
The report describes two babies with this exact gene variant, called c.497G>A (p.Cys166Tyr). Both were treated with glibenclamide and both stayed unresponsive. The report doesn't say how long they were followed or what other treatments they received.
This is a case report, not a full study. With only two patients, we can't know if all babies with this variant will fail the drug. But it's a warning: for this particular mutation, glibenclamide may not be the answer.
The report doesn't mention side effects or funding. It does say the finding gives guidance for managing iDEND patients with this variant. If your child has this condition, talk to their doctor about what this means for their care.
Common questions
What is iDEND syndrome?
iDEND stands for intermediate developmental delay, epilepsy, and neonatal diabetes. It's a rare condition caused by changes in the KCNJ11 gene. Babies with iDEND have diabetes that starts in the first six months of life, along with developmental delay and epilepsy. The report describes two infants with this syndrome and a specific KCNJ11 variant.
Why didn't glibenclamide work for these infants?
The report doesn't explain why. It only says that both infants had the same KCNJ11 c.497G>A (p.Cys166Tyr) variant and both were persistently unresponsive to glibenclamide. The study authors suggest this finding provides guidance for managing iDEND patients with this variant, but they don't offer a reason for the lack of response.
Is glibenclamide safe for infants with KCNJ11 mutations?
The report doesn't provide safety information. It doesn't mention adverse events, serious side effects, or discontinuations. Because this is a case report with only two patients, safety data are limited. Parents should discuss any treatment decisions with their child's doctor.
How many patients were in this report?
The report includes two infants. Both had iDEND syndrome and the KCNJ11 c.497G>A variant. Both were treated with glibenclamide and both did not respond. The small number means the findings may not apply to everyone with this condition.
